Cooling to Help Injured Lungs and Brain
| Reference number | |
| Coordinator | BrainCool AB (publ) |
| Funding from Vinnova | SEK 877 000 |
| Project duration | July 2020 - December 2020 |
| Status | Completed |
| Venture | Innovations to mitigate the crisis |
| Call | Finding new ways in the time of a crisis |
Important results from the project
** Denna text är maskinöversatt ** We suggested trethe atment of COVID-19 patients requiring ICU treatment. The model uses an already CE-marked and FDA-approved medical device for temperature management of patients with headaches and cardiac arrest, the BrainCool system. The goal was to treat patients to reduce the effects of both Acute Respiratory Distress Syndrome (ARDS), which often affects the seriously ill COVID-19 patients, with even higher mortality but also to act as a neuroprotective treatment for the patients to reduce the potentia brain damage and high recurrence fever
Expected long term effects
** Denna text är maskinöversatt ** Results included physiological measures, mortality, ventilator-free days, and ICU length of stay. and the severity of the brain damage that accompanies stroke. Förbättrade patient results and the reduced burden on the family: cooling contributed to the improvement of the quality of life for patients and their families.
Approach and implementation
** Denna text är maskinöversatt ** To manage and supplement the first clinical evidence for these important patients with seriously ill COVID-19 patients, the following steps were completed: 1 - Development of clinical trial protocol 2- Clinical study in COVID-19 patients 3- Clinical evaluation report and FDA package approval approved